Cost Insights: Breaking Down Corcept Therapeutics Incorporated and Cytokinetics, Incorporated's Expenses

Biotech Cost Analysis: Corcept vs. Cytokinetics

__timestampCorcept Therapeutics IncorporatedCytokinetics, Incorporated
Wednesday, January 1, 201488200044426000
Thursday, January 1, 2015136100046398000
Friday, January 1, 2016205800059897000
Sunday, January 1, 2017355400090296000
Monday, January 1, 2018521500089135000
Tuesday, January 1, 2019550400086125000
Wednesday, January 1, 2020558200096951000
Friday, January 1, 20215281000159938000
Saturday, January 1, 20225385000240813000
Sunday, January 1, 20236481000330123000
Loading chart...

Infusing magic into the data realm

Cost Insights: A Comparative Analysis of Corcept Therapeutics and Cytokinetics

In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the annual cost of revenue for Corcept Therapeutics Incorporated and Cytokinetics, Incorporated from 2014 to 2023. Over this period, Corcept Therapeutics saw a steady increase in costs, peaking at approximately $6.5 million in 2023, a growth of over 600% from 2014. In contrast, Cytokinetics experienced a more dramatic rise, with costs surging from $44 million in 2014 to a staggering $330 million in 2023, marking an increase of over 640%. This stark difference highlights the varying financial strategies and market challenges faced by these companies. As the biotech sector continues to evolve, such insights are invaluable for making informed decisions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025